{"commentary":{"count":140,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":63,"youtube":57,"x_thread":20},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02668653\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"QuANTUM-First","nct_id":"NCT02668653","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quantum-first-nct02668653. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"QuANTUM-First","arms":[{"description":"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib\n\nConsolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant\n\nContinuation: up to 36 cycles with the experimental drug quizartinib","label":"Chemotherapy plus quizartinib","type":"EXPERIMENTAL"},{"description":"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo\n\nConsolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant\n\nContinuation: up to 36 cycles with placebo","label":"Chemotherapy plus placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-06-16","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","Leukemia"],"enrollment":{"count":539,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Chemotherapy","type":"DRUG"},{"name":"Quizartinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2024-08-06","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-08-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","timeFrame":"Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment"}],"references":[{"citation":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA. Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. Blood Adv. 2026 Jun 23;10(12):4144-4159. doi: 10.1182/bloodadvances.2025017738.","pmid":"41949390","type":"DERIVED"},{"citation":"Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2026 Mar;13(3):e169-e180. doi: 10.1016/S2352-3026(25)00361-8.","pmid":"41791832","type":"DERIVED"},{"citation":"Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Zak P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444.","pmid":"41052406","type":"DERIVED"},{"citation":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP. Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. Haematologica. 2025 Sep 1;110(9):2024-2039. doi: 10.3324/haematol.2024.286623. Epub 2025 Mar 13.","pmid":"40079105","type":"DERIVED"},{"citation":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.","pmid":"37116523","type":"DERIVED"},{"citation":"Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.","pmid":"29859851","type":"DERIVED"}],"start_date":{"date":"2016-09-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","url":"https://clinicaltrials.gov/study/NCT02668653"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quantum-first-nct02668653"}